Patakfalvi A
Orv Hetil. 1996 Sep 1;137(35):1921-7.
The author surveys the action of cyclosporin, its advantages over conventional immunosuppressive drugs and its side effects. This paper lists comparative research showing autoimmune diseases in which cyclosporin has been used as well as data confined to disease causality. It touches on almost all autoimmune diseases, and details rheumatoid arthritis, lupus erythematosus disseminatus, and the treatment of kidney disease, giving a review of the ideal usage of cyclosporin during laboratory and clinical testing and the reasons for dosage modifications. In organ transplants, it is necessary to determine the serum level of cyclosporin. In autoimmun diseases cyclosporin's effectiveness and side effects cannot be determined on the basis of blood serum level. Dose modifications should be based on serum creatinine levels and on diastolic blood pressure. On the basis of the literature and on his own experience, the author emphasizes the potential for new perspectives in drug usage. This is particularly true for Sandimmun-Neoral. His group for example has been the first to use Cyclosporin A to treat Polyglandular autoimmune syndrome and Henoch Schönlein disease and has achieved excellent results.
作者综述了环孢素的作用、相较于传统免疫抑制药物的优势及其副作用。本文列出了比较研究，展示了已使用环孢素的自身免疫性疾病以及局限于疾病因果关系的数据。它几乎涉及了所有自身免疫性疾病，并详述了类风湿关节炎、系统性红斑狼疮以及肾脏疾病的治疗，回顾了环孢素在实验室和临床试验中的理想用法以及剂量调整的原因。在器官移植中，有必要测定环孢素的血清水平。在自身免疫性疾病中，不能根据血清水平来确定环孢素的有效性和副作用。剂量调整应基于血清肌酐水平和舒张压。基于文献和自身经验，作者强调了药物使用新视角的潜力。对于新山地明（Sandimmun-Neoral）尤其如此。例如，他的团队率先使用环孢素A治疗多腺体自身免疫综合征和过敏性紫癜，并取得了优异的成果。
